Dutasteride is FDA-approved for bph/">benign prostatic hyperplasia only, and no topical dutasteride product is FDA-approved, so this use is off-label. The strongest efficacy data comes from a 2025 Phase II trial (Panuganti VK et al., Cureus 2025;17(8):e89309), in which topical dutasteride 0.05% raised target area hair count within 1 cm² by 75.52 hairs at 24 weeks, against 0.07 for placebo and 41.21 for oral finasteride 1 mg. The 0.01% and 0.02% solutions also beat placebo, though the 0.02% arm gained slightly less than the 0.01% arm. No irritation was reported in the active treatment groups.
2025 Phase II Trial Results
This randomized, double-blind, placebo- and active-controlled trial enrolled 135 men aged 20 to 60 with androgenetic alopecia. Participants were randomized to topical dutasteride 0.01%, 0.02% or 0.05%, to oral finasteride 1 mg, or to placebo, applied or taken once daily for 24 weeks. The primary endpoint was change from baseline in target area hair count (TAHC) within 1 cm² at the vertex at week 24.
| Treatment group | Mean change in hair count within 1 cm² at 24 weeks | P value vs baseline |
|---|---|---|
| Topical dutasteride 0.01% (n = 28) | +32.32 | 0.0006 |
| Topical dutasteride 0.02% (n = 27) | +27.48 | 0.0037 |
| Topical dutasteride 0.05% (n = 29) | +75.52 | 0.0001 |
| Oral finasteride 1 mg (n = 29) | +41.21 | 0.0001 |
| Placebo (n = 15) | +0.07 | 0.9957 |
The 0.05% solution was significantly better than oral finasteride 1 mg on the primary endpoint (mean difference 34.30 hairs, p = 0.0083). The trial reported no significant change in serum testosterone or DHT in any dutasteride group at week 12 or week 24, so the concentrations tested cannot be ranked by systemic DHT suppression from this data.
Read the full trial analysis · Topical dutasteride overview
Sources
- Panuganti VK, et al. A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia. Cureus. 2025;17(8):e89309. PMC12405733